Pomide 2mg \u0111\u01b0\u1ee3c s\u1ea3n xu\u1ea5t b\u1edfi Hetero Healthcare Limited.<\/strong><\/p>\nPomide 2mg l\u00e0 thu\u1ed1c g\u00ec?<\/h2>\nTh\u00e0nh ph\u1ea7n<\/h3>\n
M\u1ed7i vi\u00ean nang Pomide 2mg<\/strong> ch\u1ee9a:<\/p>\n\n- Ho\u1ea1t ch\u1ea5t: Pomalidomide<\/strong>…………………2 mg<\/li>\n
- T\u00e1 d\u01b0\u1ee3c: v\u1eeba \u0111\u1ee7<\/li>\n<\/ul>\n
Tr\u00ecnh b\u00e0y<\/h3>\n
S\u0110K: \u0111ang c\u1eadp nh\u1eadt<\/p>\n
Quy c\u00e1ch \u0111\u00f3ng g\u00f3i: H\u1ed9p 1 l\u1ecd x 21 vi\u00ean<\/p>\n
Xu\u1ea5t x\u1ee9: \u1ea4n \u0110\u1ed9<\/p>\n
T\u00e1c d\u1ee5ng c\u1ee7a thu\u1ed1c Pomide 2mg<\/h2>\nC\u01a1 ch\u1ebf t\u00e1c d\u1ee5ng<\/h3>\n
Pomide 2mg \u0111i\u1ec1u tr\u1ecb b\u1ec7nh \u0111a u t\u1ee7y<\/figcaption><\/figure>\nPomalidomide l\u00e0 m\u1ed9t d\u1eabn xu\u1ea5t c\u1ee7a thalidomide v\u00e0 thu\u1ed9c nh\u00f3m thu\u1ed1c \u0111i\u1ec1u h\u00f2a mi\u1ec5n d\u1ecbch. C\u01a1 ch\u1ebf ho\u1ea1t \u0111\u1ed9ng c\u1ee7a pomalidomide r\u1ea5t ph\u1ee9c t\u1ea1p, bao g\u1ed3m kh\u1ea3 n\u0103ng t\u0103ng c\u01b0\u1eddng \u0111\u00e1p \u1ee9ng mi\u1ec5n d\u1ecbch qua trung gian t\u1ebf b\u00e0o T v\u00e0 t\u1ebf b\u00e0o NK (t\u1ebf b\u00e0o gi\u1ebft t\u1ef1 nhi\u00ean), \u1ee9c ch\u1ebf s\u1ea3n xu\u1ea5t c\u00e1c cytokine g\u00e2y vi\u00eam v\u00e0 ng\u0103n ch\u1eb7n s\u1ef1 h\u00ecnh th\u00e0nh m\u1ea1ch m\u00e1u m\u1edbi. Ngo\u00e0i ra, thu\u1ed1c c\u00f2n c\u00f3 t\u00e1c \u0111\u1ed9ng tr\u1ef1c ti\u1ebfp l\u00ean c\u00e1c t\u1ebf b\u00e0o ung th\u01b0, g\u00e2y ch\u1ebft t\u1ebf b\u00e0o th\u00f4ng qua vi\u1ec7c \u1ee9c ch\u1ebf con \u0111\u01b0\u1eddng t\u00edn hi\u1ec7u proteasome.<\/p>\n
\u0110\u1eb7c \u0111i\u1ec3m d\u01b0\u1ee3c \u0111\u1ed9ng h\u1ecdc<\/h3>\n